Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 19079346)

1.

Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.

Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD, Kleer CG.

Oncogene. 2009 Feb 12;28(6):843-53. doi: 10.1038/onc.2008.433. Epub 2008 Dec 15.

2.

Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.

Gonzalez ME, DuPrie ML, Krueger H, Merajver SD, Ventura AC, Toy KA, Kleer CG.

Cancer Res. 2011 Mar 15;71(6):2360-70. doi: 10.1158/0008-5472.CAN-10-1933.

3.

EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.

Li T, Cai J, Ding H, Xu L, Yang Q, Wang Z.

Cancer Biol Ther. 2014 Mar 1;15(3):271-8. doi: 10.4161/cbt.27306. Epub 2013 Dec 12.

4.

EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.

Moore HM, Gonzalez ME, Toy KA, Cimino-Mathews A, Argani P, Kleer CG.

Breast Cancer Res Treat. 2013 Apr;138(3):741-52. doi: 10.1007/s10549-013-2498-x. Epub 2013 Mar 29.

5.

Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.

Li H, Cai Q, Godwin AK, Zhang R.

Mol Cancer Res. 2010 Dec;8(12):1610-8. doi: 10.1158/1541-7786.MCR-10-0398. Epub 2010 Nov 29.

6.

Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells.

Dimri M, Bommi PV, Sahasrabuddhe AA, Khandekar JD, Dimri GP.

Carcinogenesis. 2010 Mar;31(3):489-95. doi: 10.1093/carcin/bgp305. Epub 2009 Dec 7.

8.

Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells.

Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, Zhu YF, Wang SM.

Int J Cancer. 2007 Nov 1;121(9):1949-57.

PMID:
17621625
9.
10.

The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo.

Wei W, Chen ZJ, Zhang KS, Yang XL, Wu YM, Chen XH, Huang HB, Liu HL, Cai SH, Du J, Wang HS.

Cell Death Dis. 2014 Oct 2;5:e1428. doi: 10.1038/cddis.2014.398.

PMID:
25275589
11.

Significance of PELP1 in ER-negative breast cancer metastasis.

Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A, Ahn JM, Raj GV, Tekmal RR, Sun L, Vadlamudi RK.

Mol Cancer Res. 2012 Jan;10(1):25-33. doi: 10.1158/1541-7786.MCR-11-0456. Epub 2011 Nov 15.

12.

miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells.

Lee YM, Lee JY, Ho CC, Hong QS, Yu SL, Tzeng CR, Yang PC, Chen HW.

Breast Cancer Res. 2011;13(6):R116. doi: 10.1186/bcr3059. Epub 2011 Nov 23.

13.

YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK.

Chang LC, Lin HY, Tsai MT, Chou RH, Lee FY, Teng CM, Hsieh MT, Hung HY, Huang LJ, Yu YL, Kuo SC.

Br J Pharmacol. 2014 Sep;171(17):4010-25. doi: 10.1111/bph.12708. Epub 2014 Jul 25.

PMID:
24697523
14.

Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.

Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA.

Clin Cancer Res. 2006 Feb 15;12(4):1168-74.

15.

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.

Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, Nederlof P, Yu Q, Jonkers J, van Lohuizen M, Pietersen AM.

Breast Cancer Res. 2009;11(4):R63. doi: 10.1186/bcr2354. Epub 2009 Aug 26.

16.

The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers.

Yang C, Hayashida T, Forster N, Li C, Shen D, Maheswaran S, Chen L, Anderson KS, Ellisen LW, Sgroi D, Schmidt EV.

Cancer Res. 2011 Feb 1;71(3):937-45. doi: 10.1158/0008-5472.CAN-10-1471. Epub 2010 Dec 2.

17.

Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.

Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC.

Cancer Res. 2012 Jun 15;72(12):3091-104. doi: 10.1158/0008-5472.CAN-11-3546. Epub 2012 Apr 13.

18.

Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells.

Radestock Y, Hoang-Vu C, Hombach-Klonisch S.

Breast Cancer Res. 2008;10(4):R71. doi: 10.1186/bcr2136. Epub 2008 Aug 21.

19.

EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.

Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R, Cristofanilli M.

J Exp Clin Cancer Res. 2013 Sep 27;32:70. doi: 10.1186/1756-9966-32-70.

20.

EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.

Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC.

Cancer Cell. 2011 Jan 18;19(1):86-100. doi: 10.1016/j.ccr.2010.10.035. Epub 2011 Jan 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk